<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="273">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157594</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A01907-34</org_study_id>
    <nct_id>NCT05157594</nct_id>
  </id_info>
  <brief_title>hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors</brief_title>
  <acronym>PROGLIO</acronym>
  <official_title>Pilot Study of hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ECS Progastrin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROGLIO is a French mono-centric study with longitudinal follow-up, in which patients with&#xD;
      high grade brain tumors will be included. Blood samples will be taken during their&#xD;
      therapeutic follow-up to evaluate plasma concentrations of hPG80 (circulating progastrin).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of hPG80</measure>
    <time_frame>From Radiotherapy 1st session to 9 month follow-up</time_frame>
    <description>To evaluate plasma concentrations of hPG80 (circulating progastrin) during therapeutic and recurrence follow-up in patients with high-grade brain tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hPG80 concentration according to tumor progression</measure>
    <time_frame>Through study completion, an average of 1 year and 6 months</time_frame>
    <description>To study hPG80 concentration according to tumor progression in patients with high-grade brain tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of hPG80 concentration changes to irradiation</measure>
    <time_frame>Through study completion, an average of 1 year and 6 months</time_frame>
    <description>To evaluate the sensitivity of hPG80 concentration changes to irradiation in patients with high-grade brain tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interindividual variations of hPG80 concentration</measure>
    <time_frame>Through study completion, an average of 1 year and 6 months</time_frame>
    <description>To compare the plasma expression level of hPG80 in patients with high-grade brain tumor to study interindividual variations around and during disease management.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glial Cell Tumors</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <description>A fasting blood sample will be taken on the day of the beginning and the day of the end of the radiotherapy and during the adjuvant chemotherapy (every 3 cycles). A follow-up will be performed for 9 months, with a blood sample taken every three months on the day of the follow-up MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female or male, 18 years of age or older, with a primary high-grade glial tumor&#xD;
        (Astrocytoma Grade 3; Glioblastoma; Anaplastic Oligodendroglioma) who needs to initiate&#xD;
        radiation and/or chemotherapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male 18 years of age or older.&#xD;
&#xD;
          -  Patients with a high grade primary glial tumor (Astrocytoma grade 3; Glioblastoma;&#xD;
             Anaplastic Oligodendroglioma)&#xD;
&#xD;
          -  Patients scheduled to begin radiation and/or chemotherapy.&#xD;
&#xD;
          -  Able to give informed consent to participate in the research.&#xD;
&#xD;
          -  Enrolled in a social security plan or beneficiary of such a plan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Psychological disorder (cognitive disorders, vigilance disorders, etc.) or social&#xD;
             reasons (deprivation of liberty by judicial or administrative decision) or&#xD;
             geographical reasons that could compromise the medical follow-up of the trial.&#xD;
&#xD;
          -  Refusal to participate.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier DURANDO, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MÃ©lanie CASILE, PhD Student</last_name>
    <phone>0473278005</phone>
    <phone_ext>+33</phone_ext>
    <email>melanie.casile@clermont.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judith PASSILDAS, PhD</last_name>
    <phone>0473278005</phone>
    <email>judith.passildas@clermont.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Jean PERRIN</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier DURANDO, Pr</last_name>
      <phone>0473278005</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.durando@clermont.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier DURANDO, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glial Cell Tumors</keyword>
  <keyword>Progastrin</keyword>
  <keyword>hPG80</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

